Where Early-Stage Life Sciences Companies Get Stuck Scaling Their Real Estate—and How to Move Forward (Source: Area Development)

Biotech firms face delays in programming, permitting, and infrastructure as they scale from lab to production.

The life sciences sector operates by a different set of rules than traditional commercial real estate. While general-use office buildings can accommodate a range of industries with modest modifications, life sciences facilities are highly specialized, requiring unique utilities, storage, structural specifications, and tailored layouts based on the tenant’s scientific focus, from wet and dry labs to clean rooms and biomanufacturing.

This complexity becomes most evident as companies transition from early-stage research and development (R&D) to commercialization, especially biomanufacturing. For emerging firms, the move from lab to production is not just a real estate decision — it’s a defining operational inflection point and increasingly where many encounter friction and delays.

Labspace Directory co-founders David Klein, Esq. (Inactive), CCIM, SIOR, LEED AP, MCR and Elijah (E.J.) Hodges break down where lab-to-production transitions go wrong, and why today's market conditions favor tenants who plan ahead. From underestimating programming timelines to over-relying on incubator space, the piece maps the most common missteps for early-stage biomanufacturing companies and how to avoid them.

Source: Area Development